ArticleBMC cardiovascular disorders2025
Functional characterization of a novel JPH2 variant (p.R160H) associated with dilated cardiomyopathy.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional characterization of a novel JPH2 variant (p.R160H) associated with dilated cardiomyopathy.BMC cardiovascular disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDilated cardiomyopathy (DCM) is a genetic cardiac disorder characterized by ventricular dilation and systolic dysfunction. Mutations in calcium-handling genes such as JPH2, which plays a critical role in maintaining cardiac dyad integrity, have been associated with DCM. Although more than 20 JPH2 variants have been reported, most lack functional validation. This study investigates the ClinVar-listed JPH2 p.R160H variant and provides initial cellular evidence related to its pathogenic potential, based on genetic data and stress-response assays.
methodsA 33-year-old male with severe DCM (LVEF 26%) and asymptomatic parents underwent trio-based whole-exome sequencing (WES). Rare variants were filtered (MAF < 0.01) and prioritized using ACMG guidelines. The JPH2 p.R160H variant was cloned and transfected into AC16 cardiomyocytes. Protein expression levels of MYH7, α-SMA, and TGF-β were assessed by Western blotting. Evolutionary conservation of R160 was evaluated using ClustalX.
resultsTrio-based WES identified a de novo JPH2 p.R160H variant absent in both parents and population controls. AC16 cells expressing the mutant construct showed increased levels of myocardial stress markers (MYH7, α-SMA, and TGF-β). JPH2 protein expression was also elevated, indicating possible dysregulation of protein turnover or stability. Evolutionary analysis confirmed that R160 is highly conserved across species. According to ACMG criteria (PS2, PS3, PM2, PP4), the variant was classified as pathogenic.
conclusionThis study provides preliminary cellular evidence supporting the pathogenic potential of the JPH2 p.R160H variant, while the direct effects on calcium handling and dyad integrity remain unknown.The combined genetic and cellular data contribute to more accurate variant classification and support the inclusion of JPH2 in cardiomyopathy genetic screening. Further mechanistic studies—particularly those assessing calcium handling—are warranted to elucidate the broader functional impact of this variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.